AUTHORS
David Bond, MD, BS, Ashley McCook, MPH2, Jeffrey Switchenko3, Katelin Baird, BS4, Narendranath Epperla, MD, MS, FACP5, Allison Marie Bock, MD6, Harsh Rohit Shah, DO7, Yazeed Sawalha, MD8, Kami Maddocks, MD9, Gregory Kirkpatrick, MD, PhD10, Umar Farooq, MD11, Eric Mou, MD12, Joanna M Rhodes, MD, MSCE13, Javier Pinilla-Ibarz, MD PhD14, Craig Portell15, Melissa Larson, MS16, Melissa Kives17, James R. Cerhan, MD, PhD18, Brian K Link, MD19, Jonathon B. Cohen, MD, MS20, Yucai Wang, MD, PhD21
AFFILIATIONS
1 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 Emory University, Atlanta, Georgia, United States
3 Emory University, Atlanta, Georgia, United States
4 Emory University, Atlanta, Georgia, United States
5 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
6 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
7 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
8 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
10 University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
11 University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
12 University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
13 Rutgers University, New Brunswick, New Jersey, United States
14 Moffitt Cancer Center, Tampa Bay, Florida, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Emory University, Atlanta, Georgia, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
20 Emory University, Atlanta, Georgia, United States
21 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction: The management of relapsed or refractory (R/R) mantle cell lymphoma (MCL) has changed significantly in recent years with the availability of multiple new classes of therapy. New drug approvals for R/R MCL have been granted primarily based on single-arm phase II studies, but contemporary real-world data regarding outcomes for R/R MCL are lacking. To provide a benchmark for interpreting recent and forthcoming studies for R/R MCL and identify unmet needs, we analyzed second- and third-line survival for patients (pts) enrolled in two prospective observational registries.
Methods: Pts with R/R MCL who received second-line therapy were identified from two registries: 1. Lymphoma Innovations ORIEN Network (LION), a prospective observational study enrolling pts with relapsed MCL at seven US academic centers, beginning in February 2020, and 2. Molecular Epidemiology Resource (MER) of the University of Iowa and Mayo Clinic, an observational study that consents pts within 6 months of initial diagnosis. Pts with MCL enrolled in MER between 2002-2015 and treated for relapsed disease between 2015-2022 were included in this analysis. Records were reviewed to avoid duplication between registries.
Survival outcomes were analyzed using Kaplan-Meier methods. Overall survival (OS) was defined from start of treatment until death from any cause and event free survival (EFS) was defined from start of treatment until either progression of disease, start of new treatment, or death. Survival was compared using log-rank test. Univariate and multivariate Cox proportional hazards models were constructed to identify prognostic factors for OS.
Results: We identified 380 evaluable pts with R/R MCL consented to either prospective registry. Median age at diagnosis was 64 years; disease relapse within 24 months from completion of frontline treatment (POD24) was present in 180 patients. Median follow-up from first relapse was 84 months (95% CI 71-93).
Among all pts, the median OS from first relapse (OS2) was 72 months (95% CI 64-85) and median EFS from first relapse (EFS2) was 21 months (95% CI 16-24). The two most common categories of second-line treatments were BTK inhibitor (BTKi) in 127 pts and chemo-immunotherapy (CIT) in 104 pts. Survival was similar between second-line BTKi vs CIT, with median OS2 of 72 vs 76 months (p=0.49) and median EFS2 of 28 vs 18 months (p=0.27). On multivariate analysis including age, POD24 status, and class of second-line treatment (BTKi v CIT), risk factors for inferior OS2 were older age (hazard ratio [HR] 1.04, 95% CI 1.03-1.06, p<0.001) and POD24 (HR 2, 95% CI 1.5-2.7, p<0.001). The median OS2 was 51 (95% CI 34-64) months for those with POD24 vs 130 (95% CI 77-147) months in pts without POD24 (p<0.001).
There were 242 pts with second disease relapse who received third-line treatment. Median follow-up from second relapse was 60 months (95% CI 44-77). The median OS from second relapse (OS3) was 46 (95% CI 37-57) months and the median EFS from second relapse (EFS3) was 15 (95% CI 11-18) months. The most common classes of third-line treatment were BTKi in 69 pts, CIT in 37 pts, and CAR-T in 18 pts. Comparing survival by third line treatment category, the median OS3 was 52 months (95% CI 43-102) with BTKi, 29 months (95% CI 12-60) with CIT, and 46 months (95% CI 25 – not reached [NR]) with CAR-T(p=0.03). The median EFS3 was 24 months (95% CI 19-36) with BTKi, 11 months (95% CI 7-19) with CIT, and NR (95% CI 7-NR) with CAR-T (p=0.03).
In the third-line cohort, 71 pts had received second-line BTKi. Reasons for BTKi discontinuation were disease progression in 59, adverse events in 4, and not recorded for 8 pts. The median OS3 was 52 months (95% CI 29-60), and the median EFS3 in this cohort was 13 months (95% CI 10-19).
Conclusions: We observed favorable OS after second- and third-line treatment among pts with relapsed MCL in two contemporary prospective observational registries. Consistent with prior findings, POD24 was strongly associated with inferior OS2. We observed inferior OS3 and EFS3 among pts treated with CIT compared with BTKi or CAR-T in third-line. Prior studies report dismal outcomes among pts with multiply relapsed disease after discontinuation of BTKi therapy; however, we observed similar third-line survival in pts treated with BTKi in second line compared with the overall study population. These findings provide context for interpreting recent and future prospective studies for relapsed MCL.
DISCLOSURES
David Bond, MD, BS: OncLive - Honoraria; Accutar - Research Funding; Genmab - Research Funding; Kite Pharma - Research Funding; Nurix Therapeutics - Research Funding; Bristol Myers Squibb - Research Funding; Incyte Corporation - Research Funding; BeOne Medicines, Ltd - Research Funding; ADC Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)